Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?
Multiple myeloma (MM) is a good target disease in which one can apply cellular immunotherapy, which is based on the graft-versus-myeloma effect. This role of immune effector cells provides the framework for the development of immune-based therapeutic options that use antigen-presenting cells (APCs)...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2012/397648 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849411598540603392 |
|---|---|
| author | Thanh-Nhan Nguyen-Pham Yoon-Kyung Lee Hyeoung-Joon Kim Je-Jung Lee |
| author_facet | Thanh-Nhan Nguyen-Pham Yoon-Kyung Lee Hyeoung-Joon Kim Je-Jung Lee |
| author_sort | Thanh-Nhan Nguyen-Pham |
| collection | DOAJ |
| description | Multiple myeloma (MM) is a good target disease in which one can apply cellular immunotherapy, which is based on the graft-versus-myeloma effect. This role of immune effector cells provides the framework for the development of immune-based therapeutic options that use antigen-presenting cells (APCs) with increased potency, such as dendritic cells (DCs), in MM. Current isolated idiotype (Id), myeloma cell lysates, myeloma dying cells, DC-myeloma hybrids, or DC transfected with tumor-derived RNA has been used for immunotherapy with DCs. Immunological inhibitory cytokines, such as TGF-β, IL-10, IL-6 and VEGF, which are produced from myeloma cells, can modulate antitumor host immune response, including the abrogation of DC function, by constitutive activation of STAT3. Therefore, even the immune responses have been observed in clinical trials, the clinical response was rarely improved following DC vaccinations in MM patients. We are going to discuss how to improve the efficacy of DC vaccination in MM. |
| format | Article |
| id | doaj-art-5d5f60a771f94efca07cc35422e371b8 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-5d5f60a771f94efca07cc35422e371b82025-08-20T03:34:44ZengWileyClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/397648397648Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?Thanh-Nhan Nguyen-Pham0Yoon-Kyung Lee1Hyeoung-Joon Kim2Je-Jung Lee3Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo 519-763, Republic of KoreaResearch Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo 519-763, Republic of KoreaDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, 160 Seoyangro, Hwasun, Jeollanamdo 519-763, Republic of KoreaResearch Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo 519-763, Republic of KoreaMultiple myeloma (MM) is a good target disease in which one can apply cellular immunotherapy, which is based on the graft-versus-myeloma effect. This role of immune effector cells provides the framework for the development of immune-based therapeutic options that use antigen-presenting cells (APCs) with increased potency, such as dendritic cells (DCs), in MM. Current isolated idiotype (Id), myeloma cell lysates, myeloma dying cells, DC-myeloma hybrids, or DC transfected with tumor-derived RNA has been used for immunotherapy with DCs. Immunological inhibitory cytokines, such as TGF-β, IL-10, IL-6 and VEGF, which are produced from myeloma cells, can modulate antitumor host immune response, including the abrogation of DC function, by constitutive activation of STAT3. Therefore, even the immune responses have been observed in clinical trials, the clinical response was rarely improved following DC vaccinations in MM patients. We are going to discuss how to improve the efficacy of DC vaccination in MM.http://dx.doi.org/10.1155/2012/397648 |
| spellingShingle | Thanh-Nhan Nguyen-Pham Yoon-Kyung Lee Hyeoung-Joon Kim Je-Jung Lee Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve? Clinical and Developmental Immunology |
| title | Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve? |
| title_full | Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve? |
| title_fullStr | Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve? |
| title_full_unstemmed | Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve? |
| title_short | Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve? |
| title_sort | immunotherapy using dendritic cells against multiple myeloma how to improve |
| url | http://dx.doi.org/10.1155/2012/397648 |
| work_keys_str_mv | AT thanhnhannguyenpham immunotherapyusingdendriticcellsagainstmultiplemyelomahowtoimprove AT yoonkyunglee immunotherapyusingdendriticcellsagainstmultiplemyelomahowtoimprove AT hyeoungjoonkim immunotherapyusingdendriticcellsagainstmultiplemyelomahowtoimprove AT jejunglee immunotherapyusingdendriticcellsagainstmultiplemyelomahowtoimprove |